Found 68 matching trials
Lenvatinib, Sintilimab, and DEB-TACE With/Without HAIC for HCC >7 cm With PVTT PHASE2 This study is conducted to evaluate the efficacy and safety of lenvatinib p...
Show More Location
The Second Affiliated Hospital of Guangzhou Medical University
Learn More & Join Trial
SIRT or TACE Plus Lenvatinib and PD-(L)1 Inhibitor in High Burden HCC N/A This multicenter retrospective study evaluated the efficacy and safety of s...
Show More Location
The Second Affiliated Hospital of Guangzhou Medical University
Learn More & Join Trial
HAIC+Lenvatinib+Tislelizumab vs D-TACE+Lenvatinib+Tislelizumab for Unresectable HCC PHASE2 Drug-eluting Bead-Transarterial chemoembolization (D-TACE) is the most wide...
Show More Location
The Second Affiliated Hospital of Nanchang University
Learn More & Join Trial
HAIC + DEB-TACE + Toripalimab + Lenvatinib for Unresectable Intrahepatic Cholangiocarcinoma PHASE2 Purpose: This phase II clinical trial evaluates whether a combination of li...
Show More Location
Multiple Locations
Learn More & Join Trial
A Study of AK104+Lenvatinib in Combination With Transarterial Chemoembolization (TACE) Versus TACE in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma PHASE3 A study to evaluate cadonilimab (AK104) + lenvatinib in combination with tr...
Show More Location
Henan Cancer Hospital
Learn More & Join Trial
TACE/HAIC Combined With Lenvatinib and Sintilimab in Neoadjuvant Therapy for Intermediate-stage HCC PHASE2 The purpose of the study is to observe the effect of TACE/HAIC combined wit...
Show More Location
Third Affiliated Hospital, Sun Yat-Sen University
Learn More & Join Trial
TACE Combined With Tislelizumab, Lenvatinib, and Carvedilol for Unresectable HCC With Cirrhotic Portal Hypertension PHASE2 In China, the majority of hepatocellular carcinoma (HCC) cases stem from ch...
Show More Location
Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Department of Hepatobiliary and Pancreatic Oncology
Learn More & Join Trial
PD-1 Monoclonal Antibody, Lenvatinib and TACE in the Treatment of HCC PHASE2 The vast majority of primary liver cancer (90%) is hepatocellular carcinoma...
Show More Location
Tianjin Medical University Cancer Hospital
Learn More & Join Trial
TACE Combined With Lenvatinib and MWA in the Treatment of Locally Advanced Large Hepatocellular Carcinoma PHASE2 To explore the objective effectiveness and safety of TACE combined with Len...
Show More Location
Sun Yat-sen University Cancer Center
Learn More & Join Trial
A Single-Arm, Multicenter, Exploratory Clinical Study of TACE Combined With Iparomlimab and Tuvonralimab Injection (QL1706) and Lenvatinib for Perioperative Treatment of Resectable Hepatocellular Carcinoma PHASE2 This is a single-arm, multicenter, exploratory clinical study evaluating th...
Show More Location
The First Affiliated Hospital with Nanjing Medical University
Learn More & Join Trial